1038133--3/16/2009--HESKA_CORP

related topics
{product, candidate, development}
{regulation, change, law}
{stock, price, share}
{customer, product, revenue}
{product, market, service}
{product, liability, claim}
{personnel, key, retain}
{control, financial, internal}
{property, intellectual, protect}
{cost, regulation, environmental}
{debt, indebtedness, cash}
{acquisition, growth, future}
{stock, price, operating}
We rely substantially on third-party suppliers. The loss of products or delays in product availability from one or more third-party supplier could substantially harm our business. We may be unable to successfully market and sell our products. We operate in a highly competitive industry, which could render our products obsolete or substantially limit the volume of products that we sell. This would limit our ability to compete and maintain sustained profitability. If the third parties to whom we granted substantial marketing rights for certain of our existing products or future products under development are not successful in marketing those products, then our sales and financial position may suffer. We have historically not consistently generated positive cash flow from operations, may need additional capital and any required capital may not be available on reasonable terms or at all. Our common stock is listed on the Nasdaq Capital Market and we may not be able to maintain that listing, which may make it more difficult for you to sell your shares. Many of our expenses are fixed and if factors beyond our control cause our revenue to fluctuate, this fluctuation could cause greater than expected losses, cash flow and liquidity shortfalls. We often depend on third parties for products we intend to introduce in the future. If our current relationships and collaborations are not successful, we may not be able to introduce the products we intend to in the future. We may not be able to continue to achieve sustained profitability or increase profitability on a quarterly or annual basis. If we are unable to maintain various financial and other covenants required by our credit facility agreement we will be unable to borrow any funds under the agreement and fund our operations. Our future revenues depend on successful product development, commercialization and/or market acceptance, any of which can be slower than we expect or may not occur. Our stock price has historically experienced high volatility, which may increase in the future, and which could affect our ability to raise capital in the future or make it difficult for investors to sell their shares. The loss of significant customers could harm our operating results. Obtaining and maintaining regulatory approvals in order to market our regulated products may be costly and delay the marketing and sales of our products. Interpretation of existing legislation, regulations and rules or implementation of future legislation, regulations and rules could cause our costs to increase or could harm us in other ways. We may face costly legal disputes, including related to our intellectual property or technology or that of our suppliers or collaborators. We depend on key personnel for our future success. If we lose our key personnel or are unable to attract and retain additional personnel, we may be unable to achieve our goals. Changes to financial accounting standards may affect our results of operations and cause us to change our business practices. We may face product returns and product liability litigation in excess of or not covered by our insurance coverage or indemnities and/or warranties from our suppliers. If we become subject to product liability claims resulting from defects in our products, we may fail to achieve market acceptance of our products and our sales could substantially decline. We may be held liable for the release of hazardous materials, which could result in extensive clean up costs or otherwise harm our business.

Full 10-K form ▸

related documents
1038133--3/3/2008--HESKA_CORP
1038133--2/22/2010--HESKA_CORP
1038133--3/30/2007--HESKA_CORP
1038133--3/31/2006--HESKA_CORP
71478--3/15/2006--LIPID_SCIENCES_INC/
1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO
1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC
874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA
874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA
873303--3/16/2006--AVI_BIOPHARMA_INC
873303--3/16/2007--AVI_BIOPHARMA_INC
71478--3/28/2008--LIPID_SCIENCES_INC/
858803--12/18/2006--AVANIR_PHARMACEUTICALS
907562--3/13/2007--DYAX_CORP
1017491--3/26/2007--NEXMED_INC
1062822--3/12/2007--LEXICON_GENETICS_INC/TX
1096560--3/12/2008--SULPHCO_INC
708717--10/15/2007--ALFACELL_CORP
908259--3/14/2007--OXIGENE_INC
907562--3/3/2006--DYAX_CORP
908259--3/14/2008--OXIGENE_INC
1010086--3/13/2008--SIGA_TECHNOLOGIES_INC
943736--3/31/2006--MED-DESIGN_CORP
1017491--3/12/2008--NEXMED_INC
817785--4/4/2007--IMMUNE_RESPONSE_CORP
810509--3/31/2008--NEOPROBE_CORP
1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC
38074--6/14/2006--FOREST_LABORATORIES_INC
1020214--2/27/2006--CERUS_CORP
881890--6/12/2009--ABAXIS_INC